|Int Diag Hld
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
|Int Diag Hld Daily Update: Int Diag Hld is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IDHC. The last closing price for Int Diag Hld was US$3.59.|
Int Diag Hld has a 4 week average price of US$3.46 and a 12 week average price of US$3.26.
The 1 year high share price is US$5.46 while the 1 year low share price is currently US$2.65.
There are currently 150,112,360 shares in issue and the average daily traded volume is 256,692 shares. The market capitalisation of Int Diag Hld is £537,402,248.80.
|ncooper1: rambutan2, thank you for your post. I will read your links. however, I was not suggesting Egypt is in a 'right mess'. I am not qualified to make such an assessment: sadly, I have not even visited Egypt yet although I do plan to. My point re currency devaluation was more factual. It has depreciated relative to US$.
Do you have any views on IDHC? Do you agree my thesis above, that IDHC is fundamentally good and that its share price is being unduly impacted by Egypt and currency movements?|
|ncooper1: I'd welcome views as to why IDHC share price continues to fall. Fundamentals seem good, and the only obvious areas is Egypt being unsettled (but this is not new news).
Currencies need to be considered too: essentially Egyptian Pound depreciating vs US$ and also £ depreciating relative to US$. My understanding is that the former should not impact IDHC input costs to the extent of share price fall-and the latter should mean the share price should increase, I think!?
I've personally continued to add, but views sought.|
|rambutan2: Of course, we are talking Egypt here:
Commenting on the half-year performance and the company's outlook, IDH Chairman Lord St John of Bletso said:
"I am pleased to report that your Company has continued to perform up to market expectations despite challenges regarding the availability of foreign exchange in Egypt that, compounded by rising inflation, have had a knock-on impact on consumer spending. Egypt has recently arrived at a staff-level agreement for a three-year, USD 12 billion extended fund facility with the International Monetary Fund. Provided this is approved by the IMF's executive board, we anticipate that the implementation of the reform package it requires will bring some stability to the Egyptian Pound. We continue to invest in expanding our business in Egypt and are also exploring opportunities to expand the business into other high-growth markets."
IDH Chief Executive Officer Dr. Hend El-Sherbini added:
"Despite challenges in Egypt, our largest market, we have been successful in growing the business and maintaining our margins. In the second half of the year, we will continue to target revenue growth of 15% while maintaining EBITDA margins in our historical range of 43-45%. We have negotiated moderate price increases with key suppliers that will take effect in 2H2016 and invested after Ramadan in a targeted marketing campaign to drive recurring test revenue. We also continue to invest in expanding our branch network to reach new patients as we explore growth opportunities outside Egypt."
Int Diag Hld share price data is direct from the London Stock Exchange